摘要
目的探讨FOXO1在乳腺癌发生发展过程中的作用及其临床意义。方法选取2012年6月至2013年1月在广东医学院附属医院经病理证实的乳腺癌组织、癌旁正常乳腺组织、乳腺良性病变组织分别50例、37例、20例,采用免疫组织化学法及实时荧光定量PCR法(RT-PCR)检测各组标本的FOXO1蛋白及m RNA的表达。结果 FOXO1蛋白在癌性组的染色阳性率为46.0%,而在良性组和癌旁组中阳性率分别为75.0%、70.2%;RTPCR检测结果显示,癌性组、癌旁组、良性组的FOXO1 m RNA表达量分别为(0.526±0.011)、(0.885±0.017)、(0.841±0.026),FOXO1蛋白及FOXO1 m RNA在癌性组标本中的表达均较癌旁组及良性组明显降低,差异均有统计学意义(P<0.05)。乳腺癌组织中FOXO1蛋白的表达及FOXO1 m RNA与肿瘤大小、腋窝淋巴结转移有关(P<0.05),而与患者绝经状态、年龄、人表皮生长因子受体2(Her-2)、雌激素受体(ER)、孕激素受体(PR)及Ki-67无关(P>0.05)。结论FOXO1蛋白及m RNA的表达与乳腺癌肿瘤大小、腋淋巴结转移有关,可作为判断乳腺癌预后的生物学指标之一。
Objective To investigate the occurrence and development of FOXO1 gene process and its clinical significance in breast carcinoma. Methods The protein and m RNA expression of FOXO1 gene were detected in 50 cases of breast carcinoma, 20 cases of benign breast lesion and 37 cases of adjacent normal breast tissue by an immunohistochemical method（steptavidin peroxidase, SP） and fluorescence-based real-time reverse transcription PCR（RT-PCR）.These tissue samples were taken from the patients who admitted to the Affiliated Hospital of Guangdong Medical College from June 2012 to January 2013. Results The positive rate of FOXO1 protein in the cancer group was 46.0%,while the positive rates in the benign group and the adjacent group were respectively 75.0% and 70.2%. The results of RT-PCR showed that the expression of FOXO1 m RNA in the cancer group, the adjacent cancer group and the benign group were（0.526 ± 0.011）,（0.885 ± 0.017）,（0.841 ± 0.026）, respectively; the protein and m RNA expression of FOXO1 gene in the cancer group were significantly lower than those in the adjacent cancer group and benign group（P〈0.05）.The protein and m RNA expression of FOXO1 gene was associated with tumor size, lymph node metastasis（P〈0.05）, but it had no relationship with menopausal status, age, HER2 receptor protein（HER2）, estrogen receptor（ER）, progesterone receptor（PR）, Ki67（P〉0.05）. Conclusion The protein and m RNA expression of FOXO1 gene is associated with tumor size and axillary lymph node metastasis, which means that FOXO1 can be used as one of the biological parameters to determine the prognosis of breast carcinoma.
出处
《海南医学》
CAS
2017年第9期1383-1386,共4页
Hainan Medical Journal
作者简介
通讯作者：陈宝英。E—mail：xgjrwk@163．com.
